Covid 19 Research using Clinical Trials (Home Page)
Milk of magnesiaWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D000437 | Alcoholism NIH | 0.58 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The purpose of this study is to assess the way the body absorbs, distributes, breaks down and
eliminates radioactive BMS-986856 in healthy males.
NCT04269356 Healthy Participants Drug: BMS-986256 Drug: Milk of magnesia
Primary Outcomes
Measure: Maximum observed plasma concentration (Cmax) of [14C] BMS-986256 Time: Up to 49 days
Measure: Time to attain maximum observed plasma concentration (Tmax) of [14C] BMS-986256 Time: Up to 49 days
Measure: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)) of [14C] BMS-986256 Time: Up to 49 days
Secondary Outcomes
Measure: Incidence of Adverse Events (AEs) Time: Up to 49 days
Measure: Incidence of Serious Adverse Events (SAEs) Time: Up to 49 days
Measure: Incidence of clinically significant changes in clinical laboratory results: Hematology tests Time: Up to 49 days
Measure: Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests Time: Up to 49 days
Measure: Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Blood pressure Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Heart rate Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Respiratory rate Time: Up to 49 days
Measure: Incidence of clinically significant changes in vital signs: Body temperature Time: Up to 49 days
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters Time: Up to 49 days
Measure: Incidence of clinically significant changes in physical examination findings Time: Up to 49 days
No related HPO nodes (Using clinical trials)